Published health technology assessments in Wales in Q2 of 2022

23

Aug 2022

Health Technology Wales (HTW) is a national body working to improve the quality of care in Wales. It is funded by Welsh Government and hosted within NHS Wales but independent of both. HTW covers medical devices, diagnostics, procedures, psychological therapies, model of care, and social care support, excluding pharmaceuticals.

HTW uses a staged process of assessment by developing three types of documents. Anyone can suggest a topic, and HTW also performs active horizon scanning. The topic exploration report (TER) aimed to assess whether there is enough available evidence to proceed with a full appraisal and whether the topic meets the appraisal selection criteria. Based on the TER conclusions, HTW's Assessment Group decides whether to progress this topic further. If yes, the following two documents are developed: Evidence Appraisal Report (EAR) and Guidance (GUI). Recommendations are not mandatory; the status of HTW guidance is "adopt or justify", meaning that the local health board and other relevant bodies are expected to report on how they have considered the appraisal and guidance. If they have chosen not to adopt HTW guidance, they are asked to outline their rationale and justify their decision.

Four topics were completed in the second quarter of 2022 with the publication of EAR and Guidance. The following key conclusions were made:

  • Extreme HypoFractionated Radiotherapy (EHFRT) was recommended for routine adoption to treat localized prostate cancer;
  • The evidence supports the routine adoption of electronic blood management systems (EBMS) to support blood transfusions. EBMS reduces rates of sample rejection and blood wastage compared with paper-based systems;
  • The routine adoption is recommended for stereotactic ablative radiotherapy (SABR) to treat people with primary kidney cancer who are not suitable for surgery or other ablative techniques;
  • Evidence does not support the routine adoption of video laryngoscopy for people who require intubation in a pre-hospital setting. Economic analysis estimates that the routine adoption would be cost incurring and not cost-effective.

In Q2 of 2022, HTW's Assessment Group decided to progress the following topics to full appraisals:

Nine TERs were published in Q2 of 2022, for which HTW's Assessment Group decided not to proceed with full appraisal:

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).

The latest related news

26

Jan 2023

The updated German Uniform Evaluation Standard (EBM) catalog came into force on January 1, 2023. The EBM catalog (Einheitlicher Bewertungsmaßstab) regulates the reimbursement of services in the public outpatient sector in Germany and is updated once a quarter (four times a year). Among other changes, a new code for "zanadio" health app for follow-up and evaluation was introduced in the catalog.

Read more

25

Jan 2023

On December 31, 2022, the Decree defining the reimbursement of medical telemonitoring activities via the new framework was published in the Official Journal of the French Republic. The Decree determines the methods of evaluation of digital solutions, registration for reimbursement, modification of the registration conditions, removal and invoicing of medical telemonitoring activities, as well as the conditions for setting the reimbursement packages.

Read more

24

Jan 2023

In December 2022, NHS England launched a consultation on the preliminary 2023/25 NHS Payment Scheme, which is set for two years and will replace the National Tariff Payment System from April 2023. Two new cardiovascular categories (antibacterial envelope, mitral valve repair and replacement devices) are proposed for inclusion in the 2023/24 High Cost Device List (will be updated and reissued for 2024/25). The deadline for comments submission is January 27, 2023.

Read more

23

Jan 2023

On December 26, 2022, three more health apps were introduced in the Directory of digital health applications (DiGAs) at the Federal Office for Drugs and Medical Devices (BfArM) and thus became reimbursable. These apps can be prescribed by physicians and psychotherapists and will be reimbursed by sickness funds.

Read more

20

Jan 2023

In December 2022, the National Institute for Health and Care Research (NIHR) in England released six MedTech-related reports in its Health Technology Assessment (HTA) Journal, which concerned laser therapy in diabetic macular oedema, EarlyCDT Lung blood test, video-assisted thoracoscopic or open lobectomy, urethral slings for stress urinary incontinence, placental growth factor (PlGF) and sFlt-1 tests, and photobiomodulation in the management of oral mucositis. HTA Journal publishes research reports on the effectiveness, costs, and broader impact of health technologies for those who use, manage, and provide care in the NHS and informs National Institute for Health and Care Excellence (NICE) guidance.

Read more